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Summary
The aim of this study was to analyze proliferative verrucous leukoplakia (PVL) and oral squamous cell carcinoma 
(OSCC) for the possible presence of Epstein-Barr virus (EBV).
We studied three groups: Sub-Group 1 was composed of 10 patients with PVL, (6 of whom had developed OSCC); 
Sub-Group 2 comprised 5 patients with OSCC but no preceding PVL; and Sub-Group 3 were 5 controls with clinically 
normal oral mucosa. Oral biopsies from all cases were examined for Epstein-Barr virus (EBV) by nested PCR. 
EBV was detected  in 60% of Sub-Group 1 patients (PVL ) and in 40% of Sub-Group 2 (OSCC), but in 0%  of Sub-
Group 3 (controls). 
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Introduction
Proliferative verrucous leukoplakia (PVL), first described 
by Hansen ,  (1985), (1)   has a high risk of malignant trans-
formation to carcinoma – especially to oral squamous cell 
carcinoma (OSCC) (2-5). The aetiology of PVL is unclear 
but the aetiology of OSCC may involve tobacco, alcohol, 
and viruses including human papillomavirus (HPV) (6).
An association has also been reported between HPV and 
PVL (7-11), particularly HPV16 and HPV18, but HPV 
were found in only a small number of cases, and other 
authors have been unable to find any such association 
(12-14). For example, Campisi et al. (13) using nested 
polymerase chain reaction (PCR) – a sensitive techni-
que-  studied 58 cases of PVL compared with 90 cases of 
other oral leukoplakias and concluded that PVL is not 
more likely to be associated with HPV infection than is 
conventional leukoplakia. Using PCR we also could not 
find an association (14). 
Epstein-Barr virus (EBV) has been implicated in a range 
of malignant neoplasms, including in some studies, in the 
aetiology of OSCC (15-18) though not in all (19) but we 
have not found any study which examined the possible 
role of EBV in PVL. 
The aim of  this preliminary study was to analyze the 
possible implication of EBV in a series of patients with 
proliferative verrucous leukoplakia (PVL).
Material and Methods
The study group consisted of 20 adult subjects, with local 
ethical committee authorisation, examining oral biopsies 
by nested polymerase chain reaction (PCR). The clinical 
data of the patients are summarized in Table 1. The study 
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Case
Sub-
Group
Age Gender
Oral locations of the 
lesions
Histology EBV
1 1 75 Female Gingiva, Palate OSCC +
2 1 74 Female Gingiva, Palate, Tongue, 
Buccal mucosa
OSCC
+
3 1 90 Female Gingiva, Palate, Tongue, 
Buccal mucosa
OSCC
+
4 1 84 Female Gingiva, Tongue, Buccal 
mucosa
Verrucous 
carcinoma
+
5 1 81 Female Gingiva, Tongue, Buccal 
mucosa
Hyperkeratosis
Dysplasia
+
6 1 68 Female Gingiva, Tongue Hyperkeratosis
Dysplasia
+
7 1 57 Female Gingiva, Buccal mucosa OSCC -
8 1 79 Female Gingiva, Tongue OSCC -
9 1 78 Female Gingiva, Tongue Hyperkeratosis
Dysplasia
-
10 1 53 Female Gingiva, Tongue, Palate, 
Buccal mucosa
Hyperkeratosis
Dysplasia
-
11 2 66 Male Sof palate OSCC +
12 2 69 Male Buccal mucosa OSCC +
13 2 65 Female Gingiva OSCC -
14 2 69 Male Tongue OSCC -
15 2 37 Male Gingiva OSCC -
16 3 35 Male - No lesions -
17 3 21 Female - No lesions -
18 3 48 Female - No lesions -
19 3 45 Male - No lesions -
20 3 18 Male - No lesions -
Table 1. Clinical, histological and nested PCR results for EBV in Sub-Groups 1 (PVL); 2 (OSCC) and 3 (controls).
Sub-Group 1: PVL
Sub-Group 2: OSCC without a background 
of PVL
Sub-Group 3: Control – no lesions
EBV: PCR results positive for  Epstein-Barr 
Virus.    
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group comprised 3 sub-groups; in all three sub-groups we 
took a biopsy under local anaesthesia and divided it in two 
fragments, one for conventional histopathological analysis 
and the rest for the biomolecular study after freezing the 
sample at -80ºC. 
Sub-Group 1 were 10 patients with PVL diagnosed accor-
ding to the criteria of Hansen et al. (1), 6 of whom had 
developed oral squamous cell carcinoma (OSCC) and 
the remaining 4 had some degree of hyperkeratosis with 
dysplasia but did not show histological signs of OSCC. 
The main age of Sub-Group 1 was 71.9 years, and all were 
females. Lesional biopsy was used.
Sub-Group 2 comprised 5 patients with OSCC but without 
any background of PVL. Lesional biopsy was used.
Sub-Group 3 came from a randomly selected healthy con-
trol group - 5 patients who came for third molar removal. 
We took an incisional biopsy of  the oral mucosa in a 
clinically normal area from the third molar flap site .
All cases were examined by nested PCR for biomarkers 
of EBV, in the following way:
DNA Extraction
DNA from frozen tissue was extracted using the High 
Pure PCR Template Preparation Extraction Kit (Roche), 
following the instructions of the manufacturer: the tissue 
was incubated at 55ºC with a Roche lysis buffer and 40 µl of 
Roche proteinase K. DNA was eluted in 200µl of H2O.
DNA from oral rinse samples was extracted, after transfe-
rring the sample into a 15ml sterile tube and centrifuging 
for 2 minutes at 4000 rpm in order to obtain a cellular 
precipitate.
The precipitate was resuspended in 200µl of PBS buffer. 
The extractions were carried out using the QIAamp DNA 
blood Midi Extraction Kit (QIAGEN), following the 
instructions of the manufacturer. The DNA was eluted 
in 200 µl of H2O.
Qualitative Detection of Epstein Barr Virus (EBV) DNA 
by PCR
Detection of EBV was carried out by nested PCR. Primary 
PCR amplifications of the processed samples were perfor-
med in a reaction volume of 25 µl, containing 2.5 µl of 10X 
PCR buffer (100 mM Tris-HCl, 500 mM KCl), 2.5 µl of 
MgCl2 25 mM, 0.5 µl of 10mM dNTPs, 0.5 µl of each 20 
µM forward and reverse EBV outer primers (Table 2), 0.5 
U of Taq DNA polymerase GOLD (Applied Biosystems) 
and 5 µl of the DNA extracted from the processed samples. 
Secondary PCR amplifications were carried out under the 
same buffer conditions described for primary PCR ampli-
fication in a reaction volume of 50 µl containing forward 
and reverse EBV inner primers instead of outer ones and 
1 µl of the primary PCR. As a positive control for each 
PCR reaction, we used quantitated viral DNA from B95-8 
strain of Epstein Barr Virus (Advanced Biotechnologies, 
Inc.). Our limit of detection was 10 copies of virus per 
amplification. As a negative control, we used the same 
components described previously but without DNA.
All PCR reactions were performed in a Biometra T3 or 
in a T1 thermocycler at the same conditions: an initial 
denaturing step of 2 min at 94ºC followed by 35 cycles 
of 30 sec at 94ºC, 30 sec at 55ºC and 30 sec at 72ºC and a 
final elongation step of 5 min at 72ºC.
Presence of PCR-amplifiable DNA as well as absence of 
PCR inhibitors were tested by amplification of human 
ß-globin gene as previously described (14).
The products of amplification were visualized by elec-
trophoresis in 2% agarose gel, stained with ethidium 
bromide.
Results
The results of the study are shown in table 1. We have 
highlighted the fact that we detected EBV by nested PCR 
in 60% of Sub-Group 1 patients (PVL ) but if  we consi-
der only those patients with OSCC in Sub-Group 1, the 
EBV positivity was slightly higher at 66,6%. (Fig. 1); in 
40% of Sub-Group 2 (OSCC);  and in 0% of Sub-Group 
3 (controls). 
 Primer  Sequence [5’-3’]
EBV outerF GAGACCGAAGTGAAGGCCCT
EBV outerR GGTGCCTTCTTAGGAGCTGT
EBV innerF GCCAGAGGTAAGTGGACTTTAAT
EBV innerR GAGGGGACCCTGAGACGGGT
Fig. 1. Electrophore-
tic analysis of  PCR 
products.
Lane1: 100 pb DNA 
Ladder [GibcoBRL]; 
Lane 2: EBV detection 
PCR reaction  from a 
positive sample; Lane 3: 
positive control for EBV 
amplification; Lane 4: 
negative PCR control 
reaction.
Table 2. Primer sequences employed for qualitative detection of 
Epstein-Barr Virus [EBV] DNA. 
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Discussion
Proliferative verrucous leukoplakia (PVL) is a slow 
growing lesion which typically  affects several areas (5), 
has a high tendency to recur after treatment, and has a 
high rate of malignant transformation and a recognized 
field cancerization (20,21) which makes it  possible to 
study the implications of some viruses in this disease. In 
the present study we identified EBV in PVL and OSCC. 
However, although we detected EBV in PVL and in a 
higher percentage of patients with PVL when compared 
with the OSCC cases without PVL we have no evidence 
of any direct role of it in the aetiology as it might be a 
simple associated infection in the context of an epithelium 
with severe multiple alterations over a long period. We 
recognize that we are reporting only a small sample of 
cases to support any role of EBV in PVL or OSCC, but 
our  positive results may encourage other investigations 
with a greater number of patients.
After initial infection, it is known that EBV persists in oral 
epithelial cells and often replicates in them (17). EBV is 
the proven aetiologic agent of nasopharyngeal carcinoma 
and is also associated with oral hairy leukoplakia, lym-
phoproliferative disease, B-cell lymphomas and lymphoe-
pithelial carcinoma (22). Several authors have previously 
studied the possible implication of EBV in OSCC, but 
with controversial results (15-19). In particular, Anwar 
et al. (23), Goldenberg et al. (24), Yang et al. (25) were 
unable to implicate EBV in OSCC. In contrast, Higa et 
al. (15) found a large number of EBV infections in their 
OSCC. EBV type B was detected in 36% of EBV-related 
OSCC in Japan but other authors such as Shimakage et 
al. (17) using mRNA in situ hybridization, immunofluo-
rescence staining, reverse transcriptase-polymerase chain 
reaction (RT-PCR) and polymerase chain reaction (PCR) 
did not find EBV. This is a preliminary study about the 
possible presence of EBV within PVL, and the method 
used cannot distinguish EBV in epithelium from EBV in 
infiltrating B cells.
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